risperidone has been researched along with Weight Loss in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 7.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "This 14-week, multicenter, open-label, rater-blinded, randomized study evaluated the effects of a group-based behavioral treatment (BT) for weight loss in overweight and obese stable patients with DSM-IV schizophrenia or schizoaffective disorder who had been switched from olanzapine to risperidone." | 5.11 | Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. ( Berry, S; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, G; Turkoz, I, 2005) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 3.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity." | 1.33 | Drug-induced weight gain. ( Apovian, CM; Ness-Abramof, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Fernández, FJ | 1 |
| Schuster, JP | 1 |
| Raucher-Chéné, D | 1 |
| Lemogne, C | 1 |
| Rouillon, F | 1 |
| Gasquet, I | 1 |
| Leguay, D | 1 |
| Gierski, F | 1 |
| Azorin, JM | 1 |
| Limosin, F | 1 |
| Lindsay, RL | 1 |
| Leone, S | 1 |
| Aman, MG | 1 |
| Brar, JS | 1 |
| Ganguli, R | 1 |
| Pandina, G | 1 |
| Turkoz, I | 1 |
| Berry, S | 1 |
| Mahmoud, R | 1 |
| Andersen, TH | 1 |
| Bech, P | 1 |
| Larsen, NE | 1 |
| Ness-Abramof, R | 1 |
| Apovian, CM | 1 |
| Cohen, S | 1 |
| Glazewski, R | 1 |
| Khan, S | 1 |
| Khan, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
2 trials available for risperidone and Weight Loss
| Article | Year |
|---|---|
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Thera | 2005 |
5 other studies available for risperidone and Weight Loss
| Article | Year |
|---|---|
Telmisartan and obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Humans; Obesity; PPAR d | 2010 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; | 2012 |
Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.
Topics: Antipsychotic Agents; Child; Child Behavior Disorders; Clinical Trials as Topic; Female; Humans; Mal | 2004 |
Drug-induced weight gain.
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Obesity; Psychotropic Drugs; Risperidone; Valproic Ac | 2005 |
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
Topics: Aggression; Antipsychotic Agents; Diet; Dose-Response Relationship, Drug; Energy Intake; Humans; Int | 2001 |